NeoGenomics, Inc. (NASDAQ:NEO) Receives $19.78 Consensus Price Target from Analysts

NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) has received a consensus rating of “Moderate Buy” from the ten research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 12 month […]

Related Keywords

United Kingdom , United States , William Blair , Piper Sandler , Craig Hallum , First Light Asset Management , Schroder Investment Management Group , Brown Advisory Inc , Nasdaq , Neogenomics Inc , Clinical Services , Vanguard Group Inc , Goldman Sachs Group , Dimensional Fund Advisors , Get Free Report , Marketbeat Ratings , Light Asset Management , Fund Advisors , Investment Management Group , Get Free , Advanced Diagnostics , Neogenomics Daily ,